logo
Share SHARE
FONT-SIZE Plus   Neg

Glenmark Generics Receives Approval For Hydrocortisone Butyrate Cream USP, 0.1%

Glenmark Pharmaceuticals Ltd. said its US subsidiary Glenmark Generics Inc. had received the approval from US FDA for Hydrocortisone Butyrate Cream USP, 0.1 percent, abbreviated new drug approval (ANDA), a generic version of Locoid Lipocream.

In April 2011, Glenmark had entered into a royalty-bearing license agreement with Triax Pharmaceuticals, Astellas Pharma Europe BV and Astellas Pharma International BV to settle a patent infringement suit against the commercialization of generic version of Locoid Lipocream and agreed to launch in near the end of CY2013. Glenmark is entitled to 180 days of exclusivity with respect to its Hydrocortisone Butyrate Cream, as it is the first generic company to file an ANDA for the product.

Hydrocortisone Butyrate Cream is indicted for the Relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in adults and the treatment of mild to moderate atopic dermatitis in patients 3 months to 18 years of age.

According to ISM Health sales data, Hydrocortisone Butyrate Cream had sales of around $34 million for the 12 months ended June 30, 2013.

AT the BSE, Glenmark Pharmaceuticals shares are currently trading at Rs.530.95, up 1.55 percent from the previous close.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

More Breaking News

0 Articles
Editors Pick
Ride-sharing company Uber Technologies Inc. is partnering with aircraft manufacturers to develop an on-demand network of vertical takeoff and landing vehicles. Uber plans to roll out flying cars with a pilot in the Dallas-Fort Worth area by 2020 and flights in Dubai at Expo2020, Chief Product Officer... Subway, the largest restaurant chain in the US by number of locations, closed more stores than it opened in 2016. This for the first time in its history that the company's store count dropped slightly after it closed more stores than it opened in 2016. The chain has always touted that it had more... Twitter Inc. reported narrower net loss in its first quarter and higher adjusted EBITDA margin as it remains focused on streamlining cost structure. Revenues declined on lower advertising and US revenues. However, adjusted earnings per share and revenues topped market estimates. In pre-market activity on the NYSE, Twitter shares were gaining 10.5 percent.
comments powered by Disqus
Follow RTT